Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Sanjosé Llongueras, Silvia de
• dc.contributor.author Serrano, Beatriz
• dc.contributor.author Tous, Sara
• dc.contributor.author Alejo, María
• dc.contributor.author Lloveras Rubio, Belen
• dc.contributor.author Quirós, Beatriz
• dc.contributor.author Clavero, Omar
• dc.contributor.author Vidal, August
• dc.contributor.author Ferrándiz-Pulido, Carla
• dc.contributor.author Pavón, Miquel Ángel
• dc.contributor.author Holzinger, Dana
• dc.contributor.author Halec, Gordana
• dc.contributor.author Tommasino, Massimo
• dc.contributor.author Quint, Wim
• dc.contributor.author Pawlita, Michael
• dc.contributor.author Muñoz, Nubia
• dc.contributor.author Bosch José, Francesc Xavier, 1947-
• dc.contributor.author Alemany, Laia
• dc.contributor.author RIS Human papillomavirus (HPV) TT study group
• dc.contributor.author Head and Neck study group
• dc.date.accessioned 2020-02-04T08:33:11Z
• dc.date.available 2020-02-04T08:33:11Z
• dc.date.issued 2019
• dc.description.abstract Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
• dc.format.mimetype application/pdf
• dc.identifier.citation Sanjosé S de, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B. et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019 Jan 7;2(4):pky045. DOI: 10.1093/jncics/pky045
• dc.identifier.doi http://dx.doi.org/10.1093/jncics/pky045
• dc.identifier.issn 2515-5091
• dc.identifier.uri http://hdl.handle.net/10230/43468
• dc.language.iso eng
• dc.publisher Oxford University Press
• dc.rights Copyright © The Author(s) 2019. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Papil·lomavirus -- Malalties
• dc.subject.other Càncer
• dc.title Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion